EYEPOINT PHARMACEUTICALS INC (EYPT)
US30233G2093 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 271.01M | 281.26M | 95.60M | 178.60M | 44.90M | |||
| Marketable Securities | 28.34M | 49.79M | 48.90M | 33.00M | N/A | |||
| Receivables | 3.02M | 805.00K | 15.50M | 18.40M | 9.50M | |||
| Inventories | 4.26M | 3.91M | 2.90M | 3.60M | 5.30M | |||
| Other Current Assets | 11.09M | 9.04M | 9.90M | 4.20M | 3.40M | |||
| Total Current Assets | 317.71M | 344.80M | 172.80M | 237.70M | 63.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 11.39M | 10.23M | 7.40M | 2.70M | 3.20M | |||
| Intangibles | N/A | N/A | 0.00 | 22.70M | 25.20M | |||
| Other Non-Current Assets | 150.00K | 150.00K | 200.00K | 200.00K | 200.00K | |||
| Total Non-Current Assets | 11.54M | 10.38M | 7.60M | 25.70M | 28.60M | |||
| TOTAL ASSETS | 329.25M | 355.18M | 180.40M | 263.40M | 91.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 10.50M | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | 0.00 | 100.00K | 100.00K | |||
| Accrued Expenses | 15.94M | 17.52M | 16.90M | 15.10M | 9.00M | |||
| Accounts Payable | 7.08M | 30.53M | 5.90M | 7.40M | 4.80M | |||
| Other Current Liabilities | 39.56M | 39.24M | 1.20M | 1.10M | 900.00K | |||
| Total Current Liabilities | 62.58M | 63.26M | 34.50M | 23.70M | 14.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 29.30M | 36.60M | 38.00M | |||
| Other Non-Current Liabilities | 16.73M | 25.60M | 20.10M | 18.70M | 20.20M | |||
| Total Non-Current Liabilities | 16.73M | 25.60M | 49.50M | 55.30M | 58.30M | |||
| TOTAL LIABILITIES | 79.31M | 88.86M | 84.00M | 79.00M | 73.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -771.43M | -742.15M | -671.40M | -569.10M | -510.70M | |||
| Additional Paid In Capital | 1.02B | 1.01B | 766.90M | 752.60M | 528.40M | |||
| Common Shares | 50.00K | 49.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 836.00K | 864.00K | 800.00K | 800.00K | 800.00K | |||
| Shares Outstanding | 49.89M | 49.04M | 34.10M | 33.90M | 18.10M | |||
| Tangible Book Value per Share | 5.01 | 5.43 | 2.83 | 4.77 | -0.37 | |||
| Total Shareholders' Equity | 249.93M | 266.32M | 96.40M | 184.40M | 18.50M | |||
| TOTAL LIABILITIES AND EQUITY | 329.25M | 355.18M | 180.40M | 263.40M | 91.70M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | 0.41 | 0.20 | 2.05 | |||
| Current Ratio | 5.08 | 5.45 | 5.01 | 10.03 | 4.23 | |||
| Return On Assets (ROA) | -23.97% | -19.93% | -56.68% | -22.18% | -49.50% | |||
| Return On Equity (ROE) | -31.57% | -26.58% | -106.07% | -31.68% | -245.35% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD